Curis (CRIS) Expected to Announce Earnings on Tuesday
by Jessica Moore · The Cerbat GemCuris (NASDAQ:CRIS – Get Free Report) is anticipated to post its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect the company to announce earnings of ($0.3267) per share and revenue of $1.6870 million for the quarter. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 5, 2026 at 8:30 AM ET.
Curis (NASDAQ:CRIS – Get Free Report) last released its quarterly earnings results on Thursday, March 19th. The biotechnology company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The business had revenue of $1.14 million during the quarter, compared to the consensus estimate of $3.25 million. On average, analysts expect Curis to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Curis Stock Performance
Shares of NASDAQ CRIS traded down $0.00 during trading on Tuesday, reaching $0.58. The stock had a trading volume of 21,291 shares, compared to its average volume of 612,439. The company has a market cap of $23.23 million, a P/E ratio of -0.49 and a beta of 3.15. Curis has a fifty-two week low of $0.49 and a fifty-two week high of $3.13. The business’s 50-day moving average price is $0.79 and its 200-day moving average price is $1.04.
Hedge Funds Weigh In On Curis
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Armistice Capital LLC grew its position in shares of Curis by 8.7% during the third quarter. Armistice Capital LLC now owns 978,190 shares of the biotechnology company’s stock worth $1,624,000 after buying an additional 78,265 shares in the last quarter. Maverick Capital Ltd. lifted its stake in Curis by 7.8% in the second quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock worth $1,472,000 after acquiring an additional 49,554 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Curis by 37.3% in the fourth quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock worth $238,000 after acquiring an additional 65,404 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in Curis by 2,883,237.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock worth $228,000 after acquiring an additional 230,659 shares in the last quarter. Finally, Squarepoint Ops LLC grew its holdings in Curis by 46.2% during the 4th quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 27,343 shares in the last quarter. Hedge funds and other institutional investors own 29.97% of the company’s stock.
Wall Street Analyst Weigh In
CRIS has been the subject of a number of research analyst reports. Wall Street Zen upgraded Curis to a “hold” rating in a report on Saturday, March 28th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Curis in a research note on Monday, April 20th. Finally, HC Wainwright reissued a “buy” rating and set a $17.00 price target on shares of Curis in a research report on Friday, March 20th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $17.00.
View Our Latest Analysis on Curis
About Curis
Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.
Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.